Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Amble vs HealthRX

Amble
Graded #212

Lower grade

vs+20.299999999999997
HealthRX
Graded #8

Higher grade

The verdict

HealthRX takes it — 86.1/100 to 65.8/100.

HealthRX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A LegitScript-certified (#50087439) physician-supervised program that runs a rare oral GLP tablet alongside the usual injectables — compounded semaglutide from ~$189/mo, tirzepatide/GLP+GIP up to ~$349, with a brand Ozempic pass-through if you need it.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueHealthRX +24
61
85
Dose & formulationHealthRX +26
64
90
Clinical oversightHealthRX +8
79
87
Labs & monitoringHealthRX +30
52
82
FulfillmentHealthRX +5
81
86
Contract termsHealthRX +30
55
85
Amble · left barHealthRX · right bar

The numbers

MetricAmbleHealthRX
WeighScore65.8/10086.1/100
GradeCB
Scorecard rank#212#8
Semaglutide$179/mo (starting dose, compounded)$189/mo
Tirzepatide$289/mo (starting dose, compounded)$349/mo
CoverageAll 50 statesNot publicly listed
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyYes
Amble

Graded #212 · C

Strengths

  • Both semaglutide and tirzepatide available
  • Compounded GLP-1 access

Where it loses points

  • Limited public information on program details
HealthRX

Graded #8 · B

Strengths

  • LegitScript-certified (#50087439) — a genuine, verifiable trust signal
  • Physician-supervised intake with licensed providers
  • Both molecules plus a rare oral GLP tablet option
  • Transparent flat monthly pricing, no insurance required

Where it loses points

  • Compounded semaglutide/tirzepatide is not FDA-approved
  • Some tiers are company-stated and the public site is thin
  • Brand Ozempic is a steep pass-through (~$1,299)
  • State count is not publicly listed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard